Alendronate preserves bone mineral density in adults with sickle cell disease and osteoporosis
In this retrospective cohort of adults with SCD and osteoporosis on alendronate for a median of 48 months, we found no significant interactions between sex and changes in lumbar spine, femoral neck, or total hip BMD with alendronate. Lumbar spine BMD was stable in those on alendronate for < 5 years. Side effects of alendronate were mild, though one patient developed an atypical femoral fracture.
Authors
- Fábio Galvão
- Ana Rita Moura (ORCID: https://orcid.org/0000-0002-0994-0467)
- Kleber Yotsumoto Fertrin (ORCID: https://orcid.org/0000-0003-2637-3297)
- Babette S. Zemel (ORCID: https://orcid.org/0000-0002-6164-7348)
- Isaac Jenkins (ORCID: https://orcid.org/0000-0002-3774-3823)
- Oyebimpe Adesina (ORCID: https://orcid.org/0000-0002-3082-9114)
- Sara T. Olalla Saad
Institutions
- Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa (ZA)
- Children's Hospital of Philadelphia (US)
- Universidade Estadual de Campinas (UNICAMP) (BR)
- University of Washington (US)
- Fred Hutch Cancer Center (US)
- University of Pennsylvania (US)
- University of California, Davis (US)
Publication Details
- Journal
- Osteoporosis International
- Published
- 2024-10-22
- DOI
- https://doi.org/10.1007/s00198-024-07268-1
- Citations
- 5
- Primary Topic
- Hemoglobinopathies and Related Disorders
- Type
- article
- Field-Weighted Citation Impact
- 2.19
Funders
- Doris Duke Charitable Foundation
- National Heart, Lung, and Blood Institute